PROF. GEORGE PANAGIOTIS CHROUSOS, MD
Medical Practice at Battery Ln, Bethesda, MD
License number
Maryland 1034341
Category
Medical Practice
Type
Community Health Worker
Address
Address
4977 Battery Ln APT 820N, Bethesda, MD 20814
Phone
(240) 432-0412
Personal information
See more information about GEORGE PANAGIOTIS CHROUSOS at radaris.comName
Address
Phone
4977 Battery Ln APT 820, Bethesda, MD 20814
4977 Battery Ln #820 N, Bethesda, MD 20814
6013 Plainview Rd, Bethesda, MD 20817
8315 Brook Ln, Bethesda, MD 20814
Professional information
Dr. George P Chrousos, Bethesda MD - MD (Doctor of Medicine)
Specialties:
Pediatric Endocrinology
Address:
4977 Battery Ln SUITE 820N, Bethesda 20814
(240) 432-0412 (Phone), (301) 402-0884 (Fax)
VALID FOR US CIVIL SERVICE EMPLOYEE ON
10 Ctr Dr, Bethesda 20892
(301) 496-0207 (Phone)
(240) 432-0412 (Phone), (301) 402-0884 (Fax)
VALID FOR US CIVIL SERVICE EMPLOYEE ON
10 Ctr Dr, Bethesda 20892
(301) 496-0207 (Phone)
Certifications:
Pediatric Endocrinology, 1980, Pediatrics, 1980
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Athens / College of Medicine / School of Health Science National & Kapodistrian
Athens U Med Sch
Nyu Langone Medical Center
National Institutes Of Health Clinical Center
University of Athens / College of Medicine / School of Health Science National & Kapodistrian
Athens U Med Sch
Nyu Langone Medical Center
National Institutes Of Health Clinical Center
Evaluative Means For Detecting Inflammatory Reactivity
US Patent:
5006330, Apr 9, 1991
Filed:
Nov 30, 1988
Appl. No.:
7/277708
Inventors:
Esther M. Sternberg - Chevy Chase MD
Ronald L. Wilder - Rockville MD
George P. Chrousos - Bethesda MD
Philip W. Gold - Washington DC
Ronald L. Wilder - Rockville MD
George P. Chrousos - Bethesda MD
Philip W. Gold - Washington DC
Assignee:
The United States of America as represented by the of the Department of
Health and Human Services - Washington DC
Health and Human Services - Washington DC
International Classification:
A61K 4900, G01N 3100, G01N 3348
US Classification:
424 9
Abstract:
Inbred Lewis (LEW/N) female rats develop an arthritis in response to Group A streptococcal cell wall peptidoglycanpolysaccharide (SCW) which mimics human rheumatoid arthritis. Histocompatible Fischer (F344/N) rats, on the other hand, do not develop arthritis in response to the same SCW stimulus. To evaluate this difference in inflammatory reactivity between the two strains, the function of the hypothalamic-pituitary-adrenal axis and its ability to modulate the development of the inflammatory response was studied. It has been found that, in contrast to F344/N rats, LEW/N rats had markedly impaired plasma ACTH and corticosterone responses to SCW, recombinant human Interleukin-1 alpha (IL-1 alpha), the serotonin agonist, quipazine, and synthetic rat corticotropin-releasing hormone (CRH). In addition, LEW/N rats compared to F344/N rats had smaller adrenal glands and larger thymuses. Treatment of LEW/N rats with replacement doses of dexamethasone decreased the severity of their SCW-induced arthritis.
Evaluative Means For Detecting Inflammatory Reactivity
US Patent:
5209920, May 11, 1993
Filed:
Sep 25, 1989
Appl. No.:
7/412294
Inventors:
Esther M. Sternberg - Chevy Chase MD
Ronald L. Wilder - Derwood MD
Philip W. Gold - Washington DC
George P. Chrousos - Bethesda MD
Ronald L. Wilder - Derwood MD
Philip W. Gold - Washington DC
George P. Chrousos - Bethesda MD
Assignee:
The United States of America as represented by the United States
Department of Health and Human Services - Washington DC
Department of Health and Human Services - Washington DC
International Classification:
G01N 100, G01N 3348, A61K 3760, A61K 4505
US Classification:
424 9
Abstract:
Inbred Lewis (LEW/N) female rats develop an arthritis in response to Group A streptococcal cell wall peptidoglycanpolysaccharide (SCW) which mimics human rheumatoid arthritis. Histocompatible Fischer (F344/N) rats, on the other hand, do not develop arthritis in response to the same SCW stimulus. To evaluate this difference in inflammatory reactivity between the two strains, the function of the hypothalamic-pituitary-adrenal axis and its ability to modulate the development of the inflammatory response was studied. It has been found that, in contrast to F344/N rats, LEW/N rats had markedly impaired plasma ACTH and corticosterone responses to SCW, recombinant human Interleukin-1 alpha (IL-1 alpha), the serotonin agonist, quipazine, and synthetic rat corticotropin-releasing hormone (CRH). In addition, LEW/N rats compared to F344/N rats had smaller adrenal glands and larger thymuses. Treatment of LEW/N rats with replacement doses of dexamethasone decreased the severity of their SCW-induced arthritis.